Company Performance Metrics
Mark Ziebell: General Counsel, Corporate Secretary- Kenneth Bilenberg: Group President & Chief Executive OfficerPast Role: Fujifilm Diosynth Biotechnologies, Chief Operating Officer
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of monoclonal antibodies in clinical trials for the treatment and diagnosis of cancer. The Company has two platforms and are pursuing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab, its PS-targeting agent, 124I-PGN650 (PGN650),
and its brain cancer therapy Cotara. Bavituximab is the Company’s therapeutic PS-targeting antibody. PGN650 is its PS-targeting imaging agent. The Company has conducted three randomized Phase II trials for bavituximab in combination with standard chemotherapy in both front and second-line NSCLC as well as front-line pancreatic cancer. In addition, it has four ongoing ISTs evaluating bavituximab with additional drug combinations in additional oncology indications
